Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)

Inclusion Criteria: * Japanese adult participants ≥ 18 years and ≤ 70 years at enrollment. * Participant should have newly diagnosed B-cell precursor (BCP) * Philadelphia-negative ALL in CR/CRh after induction/consolidation therapy with any MRD (+ or -). * CR/CRh as defined in Section 11.10, Appendix 10 after induction and at any time during consolidation chemotherapy with ALL MRD2008/2019/2023 protocol regimen or 3 blocks of Hyper-CVAD. * Bone marrow function as defined below: * Absolute neutrophil count (ANC) (Neutrophils) ≥500/μL * Platelets ≥50.000/μL (transfusion permitted) * Adequate renal and hepatic function: * Total bilirubin (TBL) ≤ 2.0 x upper limit of normal (ULN) (ULN; unless Gilbert's Disease or if liver involvement with leukemia) * Creatinine clearance ≥50 mL/min/1.73 m\^2 * Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 2. Exclusion Criteria: Disease Related * Current infiltration of cerebrospinal fluid (CSF) by ALL. If screening CSF demonstrates leukemic blasts, participants must receive intrathecal treatment and demonstrate negative CSF before enrollment and starting blinatumomab infusion. * Immunotherapy (eg, rituximab, alemtuzumab) within 4 weeks before start of protocol-specified therapy. Other Medical Conditions * History of relevant central nervous system (CNS) pathology or current relevant CNS pathology (e.g., seizure, paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, Parkinson's …